Anti-obesity drugs: past, present and future

R. John Rodgers¹,*, Matthias H. Tschöp² and John P. H. Wilding³

The ideal anti-obesity drug would produce sustained weight loss with minimal side effects. The mechanisms that regulate energy balance have substantial built-in redundancy, overlap considerably with other physiological functions, and are influenced by social, hedonic and psychological factors that limit the effectiveness of pharmacological interventions. It is therefore unsurprising that anti-obesity drug discovery programmes have been littered with false starts, failures in clinical development, and withdrawals due to adverse effects that were not fully appreciated at the time of launch. Drugs that target pathways in metabolic tissues, such as adipocytes, liver and skeletal muscle, have shown potential in preclinical studies but none has yet reached clinical development. Recent improvements in the understanding of peptidergic signalling of hunger and satiety from the gastrointestinal tract mediated by ghrelin, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), and of homeostatic mechanisms related to leptin and its upstream pathways in the hypothalamus, have opened up new possibilities. Although some have now reached clinical development, it is uncertain whether they will meet the strict regulatory hurdles required for licensing of an anti-obesity drug. However, GLP-1 receptor agonists have already succeeded in diabetes treatment and, owing to their attractive body-weight-lowering effects in humans, will perhaps also pave the way for other anti-obesity agents. To succeed in developing drugs that control body weight to the extent seen following surgical intervention, it seems obvious that a new paradigm is needed. In other therapeutic arenas, such as diabetes and hypertension, lower doses of multiple agents targeting different pathways often yield better results than strategies that modify one pathway alone. Some combination approaches using peptides and small molecules have now reached clinical trials, although recent regulatory experience suggests that large challenges lie ahead. In future, this polytherapeutic strategy could possibly rival surgery in terms of efficacy, safety and sustainability of weight loss.

Introduction

Obesity, most often defined as a body mass index (BMI) of ≥30 kg/m² and caused by an imbalance between energy intake and expenditure, is widely recognised as the largest and fastest growing public health problem in the developed and developing world (https://apps.who.int/infobase/Publicfiles/SuRF2.pdf). Prevalence of the disorder in adults has more than tripled in the past decade, and obesity currently affects approximately 30-35% of the general population in the USA and 25% in the UK (National Audit Office, 2001) (http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles/obesity/statistics-on-obesity-physical-activity-and-diet-england-2010). It has been estimated that, in 2005, some 400 million adults worldwide were obese, with a total of 1.6 billion being overweight (http://www.who.int/mediacentre/factsheets/fs311/en/index.html). Of particular concern is the associated epidemic of obesity in children and adolescents; the current prevalence of 7-10% in these populations is predicted to at least double by 2025 (McPherson et al., 2007), and there is strong evidence of persistence into adulthood (Freedman et al., 2001; Daniels, 2006b).

Obesity is associated with substantial increases in morbidity, premature mortality, impaired quality of life and large healthcare costs (Kopelman, 2000; Fontaine et al., 2003; Haslam and James, 2005). The major comorbidities include type 2 diabetes, metabolic syndrome, hypertension, dyslipidaemia, myocardial infarction, stroke, certain cancers, sleep apnea and osteoarthritis (Flegal et al., 2007). Indeed, obesity is blamed as a major contributing factor in over 300,000 deaths annually in the United States, with the illness-related economic costs exceeding US$100 billion per annum (Daniels, 2006a). Although prevention through education and changes to the obesogenic environment are long-term goals, treatment is required for those who are already obese. Surprisingly, however, treatment options remain quite limited. Lifestyle changes in the form of dieting and/or exercise per se do not generally produce marked or sustainable weight loss (Dansinger et al., 2005; LeBlanc et al., 2011), whereas effective psychological therapies, such as cognitive behavioural therapy, cannot easily be delivered on a mass scale (e.g. Wing et al., 2006) and long-term results are disappointing. Bariatric surgery, such as Roux-en-Y bypass or gastric banding, is much more effective in terms of weight loss, comorbidity reduction and enhanced survival (Kral and Naslund, 2007; Sjöström et al., 2007). However, owing to concerns about perioperative mortality, surgical complications and the frequent

1Behavioural Neuroscience Laboratory, Institute of Psychological Sciences, University of Leeds, LS2 9JT, UK
2Institute for Diabetes and Obesity, Helmholtz Center Munich and Technical University Munich, Ingelstaedter Landstr. 1, 85764 Neuherberg, Germany
3Department of Obesity and Endocrinology, Institute of Ageing and Chronic Disease, Clinical Sciences Centre, University Hospital Aintree, Liverpool, L9 7AL, UK
4Author for correspondence (r.j.rodgers@leeds.ac.uk)

© 2012. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.
COMMENTARY

need for reoperation, these procedures tend to be reserved for the morbidly obese (Melnikova and Wages, 2006; Field et al., 2009).

An alternative strategy to surgery is to develop therapeutic agents that can reduce body weight by decreasing the consumption or absorption of food, and/or by increasing energy expenditure (Cooke and Bloom, 2006; Sargent and Moore, 2009). Unfortunately, although avidly pursued for more than half a century, this strategy has thus far only shown limited success. Many new agents that were heralded as the answer to the obesity problem were hastily withdrawn owing to an unacceptable side-effects burden. Indeed, a recent review rather pessimistically concluded that "the history of anti-obesity drug development is far from glorious, with transient magic bullets and only a handful of agents currently licensed for clinical use" (Rodgers et al., 2010). Therefore, new treatments for obesity that are both better tolerated and more efficacious are urgently needed (Halford et al., 2010; Kennett and Clifton, 2010; Rodgers et al., 2010; Vickers et al., 2011). In this context, major recent advances in our understanding of the basic neurobiology of appetite and energy homeostasis have identified numerous targets for potential anti-obesity drug development (Wilding, 2007; Heal et al., 2009; Halford et al., 2010). The aim of this Commentary is to place these developments in context by reviewing the pharmacotherapy of obesity in terms of its past, present and future.

To set the stage, it is important to recognise that, following preclinical identification of potentially important new therapeutic agents, human drug trials progress through several phases of development. Phase I typically focuses on tolerability, safety and pharmacokinetics; Phase II on proof of concept (mechanism, efficacy and safety); Phase III on confirmation of efficacy and side-effect profile in large-scale multi-centre trials; and Phase IV on long-term monitoring and data collection following governmental approval. Application for approval from the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is made after Phase III.

The past

Centrally acting sympathomimetics, such as the amphetamine derivatives desoxyephedrine, phentermine and diethylpropion, were among the earliest pharmacological agents used for weight loss (Colman, 2005; Wilding, 2007). They were popular in the 1950s and 1960s, but growing concerns about cardiovascular risk and abuse potential led to a marked decline in their use by the early 1970s. Although still available in many countries, phentermine and diethylpropion were largely superseded in the 1970s and 1980s by the serotonin (5-HT)-releasing agents fenfluramine and dexfenfluramine. It was known from the outset that agents of this series had the potential to produce primary pulmonary hypertension, but the risk was deemed sufficiently low against the weight loss benefits. In the early 1990s, evidence of superior efficacy over either compound given alone led to the widespread use in the United States of combined treatment with phentermine and fenfluramine (Weintraub et al., 1992). However, within only a few years, reports of cardiac valvulopathy (Connolly et al., 1997), particularly when these agents were combined with phentermine, led the manufacturers to withdraw fenfluramine and dexfenfluramine from the market.

Until very recently, three agents were approved in Europe for the long-term clinical management of obesity and related metabolic syndrome: sibutramine (trade names Meridia® and Reductil®), rimonabant (Acomplia®) and orlistat (Xenical® and Alli®). Sibutramine, a dual monoamine (noradrenaline and serotonin)-reuptake inhibitor, was introduced to clinical practice in the late 1990s (McNeely and Goa, 1998; Luque and Rey, 2002) and is believed to achieve very modest weight loss by decreasing energy intake and increasing energy expenditure. However, cumulative clinical experience has identified some adverse effects, the most serious of which (cardiovascular risk) emerged as a result of a post-marketing clinical trial (James et al., 2010) and led in January 2010 to the suspension of marketing authorisations by the EMA (http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500069995.pdf). There is substantial evidence that phytocannabinoids (i.e. cannabis and its constituents) and endocannabinoids (e.g. anandamide) stimulate appetite in animals and humans, and that these effects are mediated via cannabinoid CB1 receptors in the brain and/or periphery (Kirkham, 2009). Rimonabant, a cannabinoid CB1 receptor antagonist/inverse agonist (see Box 1 for Glossary) developed in the mid-1990s, suppresses appetite and weight gain in experimental animals and, in four major clinical trials, has consistently been found to produce a placebo-subtracted weight loss of 4-5 kg (Despres et al., 2005; Van Gaal et al., 2005; Pi-Sunyer et al., 2006; Scheen et al., 2006). Although never approved in the United States, rimonabant (Acomplia®) was licensed in Europe as an anti-obesity agent by the EMA in June 2006. However, by October 2008, burgeoning reports of serious psychiatric problems (such as anxiety, depression and suicide) led to suspension of marketing authorisations by the EMA (http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014774.pdf). This decision in turn rapidly led to the termination of several CB1-receptor-antagonist-based anti-obesity drug development programmes [including those for rimonabant, tarianabant, otenabant, surinabant and ibipinabant (Plüth, 2008)].

The FDA approved orlistat for the treatment of obesity in 1998. Unlike the other weight loss agents mentioned above, which reduce appetite and/or enhance energy expenditure, orlistat inhibits pancreatic lipases, thereby reducing fat absorption from the gut by ~30% (Borgstrom, 1988). Weight loss is relatively modest (circa 3 kg at 12 months (Li et al., 2005)), but of sufficient magnitude to have beneficial effects on cardiovascular risk, as reflected by a lowering of low-density-lipoprotein (LDL) cholesterol, blood pressure and glycaemia (Broom et al., 2002; Torgerson et al., 2004). Compared with other agents, adverse effects are limited, but include diarrhoea,

---

**Box 1. Glossary**

**Agonist**: a substance that binds to a receptor molecule and produces a stimulus that results in a measurable response in the tissue.

**Antagonist**: a substance that binds to the same receptor as an agonist but fails to elicit a stimulus (so that no tissue response is produced). An antagonist can, however, block or reverse the effects of an agonist or inverse agonist.

**Inverse agonist**: a substance in which receptors exhibit constitutive activity, an inverse agonist will bind to the same receptor as an agonist, but the resulting stimulus produces the opposite response in the tissue.

**Antagonist/inverse agonist**: a substance that binds to the same receptor as an agonist, but its effects vary as a function of the presence (agonist action) or absence (inverse agonist action) of the agonist. A neutral antagonist has no inverse agonist activity.
flatulence, bloating, abdominal pain and dyspepsia (Bray and Greenway, 2007). At the time of writing, orlistat is the only weight loss agent approved for long-term clinical use in Europe.

The present

Despite the withdrawal of rimonabant and the demise of several CB1-receptor-antagonist development programmes, there are reasons to believe that we have not yet reached the end of the line for anti-obesity treatments targeting the CB1 receptor (for reviews, see Kunos et al., 2008; Bermudez-Silva et al., 2010). First, rimonabant and related compounds are not neutral CB1 receptor antagonists, but possess significant inverse agonist activity at these sites (Pertwee, 2006) (see Box 1 for Glossary). Recent preclinical evidence suggests that neutral antagonists might retain the weight loss advantages of rimonabant, but without the adverse effects of this agent (e.g. Cluny et al., 2011). Second, it is known that tolerance develops to the acute anorectic effect but not the weight loss effects of rimonabant-like compounds, and that the weight loss effect might involve CB1 receptors in peripheral tissues. This would support further development of CB1 receptor antagonists that do not cross the blood-brain barrier; indeed, several such agents have recently been reported to produce weight loss in rodent models (e.g. Chen et al., 2010; Randall et al., 2010).

Other realistic possibilities include the development of CB1 receptor partial agonists, allosteric modulators of CB1 receptors and agents that alter the levels of endocannabinoids (Bermudez-Silva et al., 2010). In addition, two other intriguing suggestions merit some attention. The first is based on the low-dose combination of rimonabant with another anorectic agent [e.g. an opioid receptor antagonist (Tallett et al., 2008; Lockie et al., 2011), the 5-HT2C receptor antagonist mCPP (Ward et al., 2008) or the gut peptide CCK-8s (Orio et al., 2011)]. These drug combinations have been shown to produce at least additive anorectic effects and, in the case of rimonabant plus the opioid receptor antagonist naloxone, a significant attenuation of rimonabant-induced pruritus (Tallett et al., 2008). The second suggestion derives from recent genomic studies suggesting that variants (polymorphisms) of the CB1 receptor gene, alone or in combination with the gene for the serotonin transporter (SLC6A4), contribute to the development of anxiety and/or depression in response to agents such as rimonabant (Lazary et al., 2011). These observations seem to offer the possibility of personalised medicine based on genetic screening for ‘high-risk’ individuals – i.e. a novel method for the safe use of centrally acting CB1 receptor antagonists. Nevertheless, the CB1 receptor remains stigmatised as a target owing to the massive disappointment surrounding Acomplia®, and even potentially promising alternative approaches understandably continue to face serious scepticism and a challenging regulatory climate.

Table 1 lists many of the agents that are either currently or have until very recently been in the anti-obesity drug development pipeline (Cooke and Bloom, 2006; Wilding, 2007; Heal et al., 2009; Sargent and Moore, 2009; Vickers et al., 2011). These treatments are aimed at diverse molecular targets in the CNS and/or periphery and, in some cases, at several targets simultaneously. The large number of potential new therapies should not be surprising given a projected market size of US$3.7 billion for a safe and effective anti-obesity drug (Vickers and Cheetham, 2007). It is beyond the scope of this article to review all the potential therapies listed in Table 1. Instead, we focus on a subset of the most promising and/or exciting lines of enquiry.

Table 1 shows that, despite successful progress up to Phase III (Vickers et al., 2011), Contrave® (a polytherapy) was recently turned down by the FDA owing to potential cardiovascular risk. Although the federal authorities still require more evidence that drug-specific concerns are unfounded, it seems probable that Contrave® will be re-filed in the near future. Lorcarserin, a monotherapy, was initially rejected in 2010 owing to concerns about tumour growth in preclinical studies but, following re-file, was approved by the FDA in June 2012: plans are to market the compound under the tradename Belviq®. Similarly, a third agent, Qnexa® (a polytherapy), was initially declined by the FDA in 2010 owing to concerns over possible birth defects but, on re-file, was FDA-approved in July 2012: this compound will apparently be marketed under the tradename Qsymia®. Two other compounds ( cetilistat, a monotherapy, and tesofensine, a polytherapy) have reached advanced Phase III testing but have not at the time of writing been formally submitted for approval in the USA or Europe. One area of substantial interest has focused on the weight loss effects of the glucagon-like peptide 1 receptor (GLP-1R) agonists that are already licensed for the treatment of type 2 diabetes. GLP-1 is an endogenous gut peptide that was initially identified as an incretin hormone (Kreymann et al., 1987) and was later found to be part of the endogenous satiety cascade (Turton et al., 2006). Modest weight loss has consistently been observed when individuals are treated for diabetes (Wilding and Hardy, 2011), but there is evidence that higher doses of the GLP-1R agonist liraglutide than are necessary for glucose lowering can produce greater weight loss of up to 10 kg in trials of up to 2 years duration (Astrup et al., 2009; Astrup et al., 2011). Unsurprisingly, an extensive programme is now underway to further test the efficacy and safety of liraglutide. Other treatments that are based largely on preclinical findings and aimed at an impressively wide range of molecular targets remain at relatively early stages of development.

The future

Traditional pharmacological monotherapies for obesity, although initially successful in achieving weight loss, are often subject to counter-regulation. This is not surprising given the multiplicity and redundancy of mechanisms involved in appetite regulation and energy homeostasis (Adan et al., 2008; Vemuri et al., 2008). It is therefore pertinent to note that two of the three treatments that were most recently submitted for FDA approval (Contrave® and Qnexa®) are effectively ‘polytherapies’ – i.e. combination agents that are designed to simultaneously target more than one biological mechanism and that might ultimately be more effective in producing sustained weight loss and improvements in comorbidities. Advantages of polytherapy, which actually began some 20 years ago with the phentermine and fenfluramine combination, include the use of lower drug doses, possible synergistic but at least additive weight loss, less serious side effects and reduced potential for counter-regulation (Greenway et al., 2009; Padwal, 2009; Roth et al., 2010).

In this context, it would seem reasonable to suggest that man-made CNS-targeted agents would be more likely to engender adverse effects than would naturally occurring biological signals that normally regulate the activity of key CNS circuits. Over the
past few decades, basic research (for reviews, see Cooke and Bloom, 2006; Field et al., 2009; Halford et al., 2010; Kennett and Clifton, 2010) has identified a host of signals emanating from the gut (e.g. CCK, ghrelin, GLP-1, glucose-dependent insulinotropic polypeptide, oxyntomodulin, PYY), pancreas (e.g. insulin, amylin, pancreatic polypeptide) and adipose tissue (e.g. leptin, adiponectin). Against this background, basic and applied research has begun to assess the therapeutic potential of combinations of these molecules – either with one another [e.g. amylin with murine leptin (Trevaskis et al., 2008)] or with a centrally acting agent [e.g. amylin or pramlintide with either phentermine or sibutramine (Roth et al., 2008; Arrone et al., 2010)]. As shown in Table 1, one such combination [pramlintide plus metreleptin (Ravussin et al., 2009)] entered Phase II clinical trials but the programme was stopped because of significant problems with antibody generation and skin reactions (http://www.takeda.com/press/article_42791.html).

Another exciting recent strategy involves the development of single-peptide molecules that combine differing modes of action. For example, Day and colleagues recently reported on a peptide with dual agonism at the glucagon receptor and GLP-1R (Day et al., 2009). Glucagon is a pancreatic hormone with well-established thermogenic, anorectic and weight loss effects in animals (Salter, 1960; Woods et al., 2006), whereas GLP-1R agonism (e.g. with exenatide) is known to improve glycaemic control and weight loss in humans with type 2 diabetes (e.g. Hanssen et al., 2009). On the basis of these observations, Day and colleagues reasoned that the antihyperglycaemic property of GLP-1R agonism could minimise any diabetogenic risk of excessive glucagon agonism. They further argued that the lipophilic and thermogenic properties of glucagon, in addition to the satiation-inducing pharmacology of GLP-1, provided a strong scientific basis for the development of a synergistic co-agonist peptide. Consistent with this rationale, the authors report that new peptides with varying ratios of agonism both at glucagon and GLP-1 receptors have potent, sustained satiation-inducing and lipolytic effects in rodents (Day et al., 2009). Detailed analysis revealed that body weight reduction was achieved by a loss of body fat arising from decreased intake and increased expenditure. The authors suggest that it is at least theoretically possible to incorporate factors other than gut hormones in an analogous single-molecule co-agonist. Furthermore, combining more than two endogenous metabolic peptides into a single molecule might lead to receptor occupancy patterns that more closely resemble physiological regulation. The development of new molecules based on this novel strategy is likely to have substantial heuristic value.

**Conclusions**

Despite an inauspicious history, the pharmacological management of obesity is at an exciting crossroads. New treatments are

<table>
<thead>
<tr>
<th>Name or code</th>
<th>Company</th>
<th>Type of agent or combination</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monotherapies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorcaserin (ADP359)</td>
<td>Arena Pharma</td>
<td>5-HT2C receptor agonist</td>
<td>FDA approved 2012, following re-file</td>
</tr>
<tr>
<td>ATHX-105</td>
<td>Athersys</td>
<td>5-HT2C receptor agonist</td>
<td>Phase II</td>
</tr>
<tr>
<td>BVT.74316</td>
<td>Biovitrum</td>
<td>5-HT3 receptor antagonist</td>
<td>Phase I</td>
</tr>
<tr>
<td>PRX-07034</td>
<td>EPIX Pharma</td>
<td>5-HT4 receptor antagonist</td>
<td>Phase I</td>
</tr>
<tr>
<td>S-2367</td>
<td>Shinogi</td>
<td>Neuropeptide Y5 receptor antagonist</td>
<td>Phase II; abandoned 2011</td>
</tr>
<tr>
<td>TM30339</td>
<td>7TM</td>
<td>Neuropeptide Y4 agonist</td>
<td>Phase I</td>
</tr>
<tr>
<td>Cetilistat</td>
<td>Alzyme/Takada</td>
<td>Lipase inhibitor</td>
<td>Phase III; abandoned?</td>
</tr>
<tr>
<td>Amylin analogue</td>
<td>Amylin</td>
<td>Amylinomimetic</td>
<td>Phase I</td>
</tr>
<tr>
<td>KRP-204</td>
<td>Kyorin</td>
<td>Selective β3-adrenoceptor agonist</td>
<td>Phase II</td>
</tr>
<tr>
<td>Remogafloxin etabonate (GSK 199075)</td>
<td>GlaxoSmithKline</td>
<td>Sodium glucose transporter-2 (SGLT-2) antagonist</td>
<td>Phase I; abandoned 2010</td>
</tr>
<tr>
<td><strong>Polytherapies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tesofensine</td>
<td>NeuroSearch</td>
<td>5-HT/DA/NA reuptake blocker</td>
<td>Phase III</td>
</tr>
<tr>
<td>Dov 21947</td>
<td>Dov Pharmaceuticals</td>
<td>5-HT/DA/NA reuptake blocker</td>
<td>Phase II</td>
</tr>
<tr>
<td>Obinutuzumab</td>
<td>7TM</td>
<td>Neuropeptide Y2 + Y4 receptor agonist</td>
<td>Phase II</td>
</tr>
<tr>
<td>Contrave</td>
<td>Orexigen</td>
<td>Bupropion + naltrexone</td>
<td>Declined FDA 2011; cardiovascular concerns; company re-file probable</td>
</tr>
<tr>
<td>Empatic</td>
<td>Orexigen</td>
<td>Bupropion + zonisamide</td>
<td>Phase II</td>
</tr>
<tr>
<td>Qnexa</td>
<td>Vivus</td>
<td>Phentermine + topiramate</td>
<td>FDA approved 2012, following re-file</td>
</tr>
<tr>
<td>Pramlintide/metreleptin</td>
<td>Amylin</td>
<td>Amylinomimetic/leptin</td>
<td>Phase II; programme terminated 2011; antibody generation</td>
</tr>
</tbody>
</table>

Based on previous research (Cooke and Bloom, 2006; Wilding, 2007; Heal et al., 2009; Sargent and Moore, 2009; Vickers et al., 2011). This table is not intended as an exhaustive list of all agents in development.

*Wyeth have since been bought out by Pfizer: plans for molecule unknown.

DA, dopamine; NA, noradrenaline; 5-HT, 5-hydroxytryptamine.
essentially on the horizon, and novel research strategies have very recently come to the fore. However, it must be emphasised that only limited behavioural data are available on many of these treatments, including those currently undergoing regulatory approval (Hafald et al., 2010; Kennett and Clifton, 2010; Rodgers et al., 2010). Much emphasis is being placed on endpoints (reduced food intake and/or body weight) and possibly not enough on process – i.e. how the endpoint has been reached. Without a much deeper understanding of molecular, physiological and behavioural mechanisms, we are likely to witness many more failed ‘magic bullets’ over the next few years. To minimise this prospect, it is essential that detailed behavioural analysis is conducted at an early stage of drug development. Given some of the molecular targets involved (e.g. monoamine transporters, CB1 receptors, 5-HT2C receptors), such analyses should ideally include not only tests of feeding behaviour but also, for example, tests relevant to mood, sexual behaviour, and learning and memory. However, even for those agents that meet preliminary requirements for selectivity of action and potential safety profile, extensive real-world testing is likely to be required by regulators, not only showing efficacy in terms of weight loss but also demonstrating long-term benefits for diabetes prevention and treatment, cardiovascular disease, and psychiatric safety. Finally, successful discovery and development of potent and safe drugs for the prevention and treatment of obesity will probably require polytherapeutic strategies as well as vastly improved tools for the identification and characterisation of specific obese subpopulations that allow for the tailor-made development and appropriate use of personalised medicines.

This article is part of a special issue on obesity: see related articles in Vol. 5, issue 5 of Dis. Model. Mech. at http://dmm.biologists.org/content/5/5.toc.

COMPETING INTERESTS

M.H.T. is a consultant for Roche Pharmaceuticals. J.P.H.W. has received consultancy and speaker fees from Novo Nordisk (manufacturers of liraglutide), and his department has active research grants from Novo Nordisk and Sanofi (who are developing GLP-1 agonists).

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

REFERENCES


COMMENTARY

Anti-obesity drugs


